Fluorescent protein labeled human serum amyloid protein A as well as preparation method and application thereof
The problems of low yield, cross infection and endotoxin contamination in the prior art are solved by expressing and purifying fluorescent protein-tagged human serum amyloid protein A (Clover-SAA1) in human embryonic kidney cells, providing high stability and high purity Clover-SAA1 protein for diagnosis and research of inflammation-related diseases.
Patent Information
- Application Number
- CN202410216077.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-27
- Publication Date
- 2025-08-29
AI Technical Summary
In the prior art, the preparation method of human serum amyloid A protein (SAA) has problems with low yield, cross-infection risk, endotoxin contamination and structural function differences, which affects its effectiveness in inflammation research and clinical application.
Human serum amyloid A protein (Clover-SAA1) labeled with fluorescent proteins was expressed in human embryonic kidney cells, and high stability and high purity Clover-SAA1 protein was obtained by purification, avoiding cross infection, and increasing yield through optimized purification steps.
The efficient and safe preparation of Clover-SAA1 protein is achieved for the diagnosis and research of inflammation-related diseases, providing stable biomarkers and visualization tools to support in-depth understanding of disease mechanisms and the development of therapeutic strategies.
Smart Images

Figure HDA0004716566280000011 
Figure HDA0004716566280000021 
Figure HDA0004716566280000031
Abstract
Description
Technical Field
[0001] The present invention relates to the field of genetic engineering, and in particular to fluorescent protein-labeled human serum amyloid A and a preparation method and application thereof. Background Art
[0002] The inflammatory response is the body's instinctive defense mechanism against external damage or internal abnormalities. This response involves the core functions of the innate immune system, with the goal of eliminating harmful stimuli and promoting the repair of damaged tissues. Because it involves a wide range of pathological conditions and treatment methods, this process is crucial in a variety of biological and medical research. When inflammation occurs, specific proteins in the serum, especially acute phase proteins (APP), will show significant changes in concentration. Serum amyloid A (SAA) is one of the acute phase proteins, and its concentration is significantly increased in both acute and chronic inflammation, making it an important biomarker in inflammatory conditions.
[0003] As our understanding of inflammation and related diseases deepens, the demand for research on SAA is growing. Therefore, SAA plays a crucial role in the development of inflammatory responses and chronic diseases, and its research is of great significance for a deeper understanding and treatment of these diseases.
[0004] Traditional methods for preparing serum amyloid are usually extracted from human serum, which has several limitations:
[0005] (1) Low yield. The concentration of SAA in human serum is very low in the non-inflammatory state, so the yield of SAA extracted from healthy individuals is limited.
[0006] (2) There are risks such as cross-infection. When SAA is extracted from human serum, there is a risk of transmitting blood-borne pathogens, such as HIV and hepatitis C virus, which poses a serious health hazard to personnel who handle samples and researchers who use SAA.
[0007] (3) There are differences in structure and function compared to SAA in human serum. Recombinant SAA proteins expressed by bacteria (such as E. coli) or yeast differ from human SAA in post-translational modifications, which affects their biological activity and immunogenicity. This difference has a significant impact on the study of the biological function of SAA and its role in clinical applications.
[0008] (4) Endotoxin contamination. SAA obtained from commercial channels is mostly purified and prepared through E. coli expression systems, which may be contaminated by endotoxins, which has a great impact on the study of the role of SAA in diseases.
[0009] In summary, the low-endotoxin, stable, reliable, and efficient SAA preparation method supports its widespread use in experimental research and clinical applications. Effective SAA preparation not only improves experimental accuracy and reproducibility but also helps deepen our understanding of the mechanisms of inflammation and related diseases. Furthermore, high-purity and high-activity SAA provides an important experimental foundation for the development of new therapeutic strategies, such as the detection of disease markers and the identification of drug targets.
[0010] Therefore, there is an urgent need in the art to develop a low-endotoxin, high-efficiency, and stable system for expressing serum amyloid A protein in mammalian cells. Summary of the Invention
[0011] The purpose of the present invention is to provide a method for preparing Clover-SAA1 protein with simple operation, high yield, no cross infection and high efficiency.
[0012] Another object of the present invention is to provide a host cell that expresses the low-endotoxin, safe, and natural Clover-SAA1 protein.
[0013] In a first aspect of the present invention, a fusion protein is provided, wherein the fusion protein has a structure shown in Formula I:
[0014] Z0-Z1-L1-Z2(I)
[0015] Where,
[0016] Z0 is a tag sequence used for purification and separation purposes;
[0017] Z1 is a fragment of human serum amyloid A protein;
[0018] L1 is none or connector;
[0019] Z2 is a fluorescent protein.
[0020] In another preferred embodiment, the tag sequence used for the purpose of purification and separation is selected from the following group: 6His, SUMO, TEV fragment, or a combination thereof.
[0021] In another preferred embodiment, the inflammatory cytokine is selected from the group consisting of IL-6, IL-1β, TNF-α, or a combination thereof.
[0022] In another preferred embodiment, the Z0 has a structure shown in Formula II:
[0023] Za-Zb-Zc-Zd(II)
[0024] Za is none or signal peptide;
[0025] Zb is none or His tag;
[0026] Zc is none or SUMO label;
[0027] Zd is none or TEV.
[0028] In another preferred embodiment, the fusion protein has a structure shown in Formula I:
[0029] Z0-Z1-L1-Z2-L2-Z3(I)
[0030] Where,
[0031] Z0 is a tag sequence used for purification and separation purposes;
[0032] Z1 is a fragment of human serum amyloid A protein;
[0033] L1 is none or connector;
[0034] Z2 is a fluorescent protein;
[0035] L2 is none or connector;
[0036] Z3 is an inflammatory cytokine.
[0037] In another preferred embodiment, the human serum amyloid A protein fragment has the amino acid sequence of positions 11 to 58 of the wild-type human serum amyloid protein A1 amino acid sequence.
[0038] In another preferred embodiment, the fusion protein has the amino acid sequence shown in SEQ ID NO: 1.
[0039] In another preferred embodiment, the human serum amyloid A protein has an amino acid sequence as shown in SEQ ID NO: 2.
[0040] In another preferred embodiment, the fluorescent protein has an amino acid sequence as shown in SEQ ID NO: 3.
[0041] In another preferred embodiment, the fluorescent protein is CLOVER protein.
[0042] In another preferred embodiment, the polynucleotide encoding the human serum amyloid A protein has a nucleotide sequence as shown in SEQ ID NO: 4.
[0043] In another preferred embodiment, the polynucleotide encoding the fluorescent protein has a nucleotide sequence as shown in SEQ ID NO: 5.
[0044] In a second aspect, the present invention provides a polynucleotide encoding the fusion protein as described in the first aspect of the present invention.
[0045] In another preferred embodiment, the polynucleotide has the nucleotide sequence shown in SEQ ID NO: 6.
[0046] The third aspect of the present invention provides a vector comprising the polynucleotide according to the second aspect of the present invention.
[0047] In another preferred embodiment, the vector comprises an expression vector.
[0048] The fourth aspect of the present invention provides a host cell, wherein the host cell contains the vector as described in the third aspect of the present invention or the polynucleotide as described in the second aspect of the present invention is integrated into its genome.
[0049] In another preferred embodiment, the host cells include prokaryotic cells and eukaryotic cells.
[0050] In another preferred embodiment, the host cells include human embryonic kidney cells, Escherichia coli, yeast, Bacillus, or insect cells.
[0051] In another preferred embodiment, the host cell is a human embryonic kidney cell.
[0052] In a fifth aspect, the present invention provides a use of the fusion protein according to the first aspect of the present invention, wherein the fusion protein is used to prepare a preparation for diagnosing human serum amyloid-related diseases.
[0053] In another preferred embodiment, the human serum amyloid protein-related disease is selected from the group consisting of rheumatoid arthritis, inflammatory bowel disease, pneumonia, cardiovascular disease, sepsis, or a combination thereof.
[0054] In another preferred embodiment, the fusion protein is used to prepare a preparation for real-time cell tracking.
[0055] In another preferred embodiment, the fusion protein is used to prepare a biomarker preparation.
[0056] In a sixth aspect, the present invention provides a method for preparing the fusion protein according to the first aspect of the present invention, the method comprising the following steps:
[0057] Under conditions suitable for expression, the host cell as described in the fourth aspect of the present invention is cultured, expression is induced, and purification is performed to obtain the fusion protein.
[0058] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. BRIEF DESCRIPTION OF THE DRAWINGS
[0059] Figure 1 The schematic diagram of the plasmid of human serum amyloid A1 (11-58) recombinant protein (His-SUMO-TEV-SAA1158 recombinant protein) is shown.
[0060] Figure 2 The schematic diagram of the plasmid of fluorescent protein-tagged human serum amyloid A1 (11-58) recombinant protein (His-SUMO-TEV-Clover-SAA1158 recombinant protein) is shown.
[0061] Figure 3 The schematic diagram of the plasmid of fluorescent protein-tagged human serum amyloid A (11-58) recombinant protein (His-SUMO-TEV-SAA1158-Clover recombinant protein) is shown.
[0062] Figure 4 The expression results of human serum amyloid A1 (11-58) recombinant protein (His-SUMO-TEV-SAA1158 recombinant protein) are shown.
[0063] Figure 5 The expression results of fluorescent protein-labeled human serum amyloid A1 (11-58) recombinant protein (His-SUMO-TEV-Clover-SAA1158 recombinant protein) are shown.
[0064] Figure 6 The expression results of fluorescent protein-labeled human serum amyloid A (11-58) recombinant protein (His-SUMO-TEV-SAA1158-Clover recombinant protein) are shown. DETAILED DESCRIPTION
[0065] After extensive and in-depth research, numerous experiments, and screening, the present invention unexpectedly discovered a fluorescent protein-labeled fusion protein of human serum amyloid A1 (Clover-SAA1). This fusion protein exhibits excellent stability and visualization, and its preparation method offers high yield, no cross-infection, and simple steps. This was the basis for the completion of the present invention.
[0066] Specifically, the present invention uses human embryonic kidney cells transfected with gene expression vectors encoding fluorescent protein and SSA1 protein, and obtains Clover-SSA1 protein through culture, screening, induction of secretion, and purification without cross infection.
[0067] the term
[0068] In order to make the present invention easier to understand, certain technical and scientific terms are specifically defined below. Unless otherwise clearly defined in this article, all other technical and scientific terms used herein have the meanings generally understood by those of ordinary skill in the art to which the present invention belongs. Before describing the present invention, it should be understood that the present invention is not limited to the specific methods and experimental conditions, because such methods and conditions can change. It should also be understood that the terms used herein are intended only to describe specific embodiments and are not intended to be restrictive, and the scope of the present invention will only be limited by the appended claims.
[0069] As used herein, the term “comprise” or variations thereof such as “include” or “comprising”, etc., is understood to include the stated elements or components but does not exclude other elements or components.
[0070] As used herein, the terms “fluorescent protein-labeled human serum amyloid A1,” “Clover-SAA1,” “recombinant protein of the present invention,” “fusion protein of the present invention,” and “fluorescent protein-labeled human serum amyloid A of the present invention” are used interchangeably and refer to the fluorescently labeled human serum amyloid A1 polypeptide prepared by the method of the present invention.
[0071] As used herein, the term "inflammatory-related diseases" refers to diseases accompanied by inflammation or caused by excessive expression of inflammatory cytokines, including but not limited to rheumatoid arthritis, atherosclerosis, cardiovascular disease, pancreatitis, pneumonia, hepatitis, diabetes, chronic kidney disease, obesity, muscle atrophy, and gout.
[0072] Human embryonic kidney cells 293
[0073] Human embryonic kidney 293 cells are a cell line derived from human embryonic kidney cells. They are characterized by high transfection efficiency and ease of culture, making them a commonly used cell line for exogenous gene expression research. Expi293f cells are a variant of human embryonic kidney 293 cells.
[0074] Fluorescent proteins
[0075] Fluorescent proteins are a class of proteins that can be excited by ultraviolet light of a specific wavelength to produce fluorescence. By co-encoding the target gene with the fluorescent protein gene, the precise localization, movement, and even aging of the target protein can be observed. Fluorescent proteins can be used for single cell labeling and tissue labeling to observe morphology, position and movement (for example, in embryonic development and tumorigenesis), mitotic stages, and many other important cellular characteristics. Finally, entire organisms can be labeled with fluorescent proteins to distinguish transgenic individuals from wild-type individuals. In addition, fluorescent proteins can be used to observe interactions between proteins in living cells and visualize the activity of target enzymes.
[0076] Clover fluorescent protein is a mutant of green fluorescent protein (GFP). Clover fluorescent protein has a longer excitation wavelength and higher quantum yield than wild-type GFP, which makes it superior in certain applications. The protein encoded by the Clover fluorescent protein gene contains 238 amino acids and can be excited by light from blue to ultraviolet light, emitting green fluorescence. The excitation wavelength of this fluorescent protein is typically between 395nm and 475nm, while the emission wavelength peaks at approximately 509nm, which is located in the green region of the visible spectrum. In the fields of cell biology and molecular biology, the Clover fluorescent protein gene is often used as a reporter gene to label and study cellular and subcellular proteins in living cells.
[0077] Serum amyloid A protein
[0078] Serum amyloid A (SAA) is one of the acute phase proteins. Its concentration increases significantly in both acute and chronic inflammation and becomes an important biomarker in inflammatory conditions.
[0079] Changes in SAA concentrations are not only indicative in clinical diagnosis but also play a key role in understanding the pathogenesis of inflammatory diseases. In particular, in chronic diseases such as Alzheimer's disease, long-term elevations in SAA can lead to the formation of amyloid A (AA) and its deposition in major organs and tissues, triggering a series of serious health problems collectively known as amyloidosis, including but not limited to organ failure.
[0080] Clover-SAA1 protein, coding sequence and preparation method
[0081] The Clover-SAA1 protein of the present invention refers to a fusion protein in which the Clover fluorescent protein is labeled at the C-terminus of the recombinant SAA protein. The Clover-SAA1 protein has good stability and can be visualized.
[0082] The Clover-SAA1 protein of the present invention is expressed in human embryonic kidney cells and does not produce endotoxins, so the Clover-SAA1 protein of the present invention has good safety.
[0083] As used herein, "isolated" means a substance that has been separated from its original environment (in the case of a naturally occurring substance, the original environment is the natural environment). For example, polynucleotides and polypeptides in their natural state within living cells are not isolated and purified. However, the same polynucleotides or polypeptides are isolated and purified if they are extracted from other substances that also exist in their natural state.
[0084] As used herein, "isolated Clover-SAA1 protein or polypeptide" means a Clover-SAA protein that is substantially free of other proteins, lipids, carbohydrates, or other substances with which it is naturally associated. Those skilled in the art can purify the Clover-SAA protein using standard protein purification techniques. A substantially pure polypeptide will produce a single major band on a non-reducing polyacrylamide gel. The purity of the Clover-SAA protein can be determined by amino acid sequence analysis.
[0085] The polypeptides of the present invention may be recombinant polypeptides, synthetic polypeptides, preferably recombinant polypeptides. The polypeptides of the present invention may be produced using recombinant techniques from prokaryotic or eukaryotic hosts (e.g., bacteria, yeast, higher plants, insects, and mammalian cells). Depending on the host used in the recombinant production protocol, the polypeptides of the present invention may be glycosylated or non-glycosylated. The polypeptides of the present invention may or may not include an initial methionine residue.
[0086] The present invention also includes fragments, derivatives, and analogs of SAA proteins. As used herein, the terms "fragment," "derivative," and "analog" refer to polypeptides that substantially retain the same biological function or activity as the native Clover-SAA protein of the present invention. The polypeptide fragments, derivatives, or analogs of the present invention may be (i) polypeptides in which one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) are substituted, and such substituted amino acid residues may or may not be encoded by the genetic code, or (ii) polypeptides having a substituent group in one or more amino acid residues, or (iii) polypeptides formed by fusion of a mature polypeptide with another compound (such as a compound that extends the half-life of the polypeptide, such as polyethylene glycol), or (iv) polypeptides formed by fusion of an additional amino acid sequence to the polypeptide sequence (such as a leader sequence or secretory sequence, or a sequence used to purify the polypeptide, or a proprotein sequence, or a fusion protein with 6His). Based on the teachings herein, these fragments, derivatives, and analogs are well known to those skilled in the art.
[0087] In the present invention, the term "Clover-SAA1 protein" refers to a polypeptide having the sequence set forth in SEQ ID NO: 1. The term also encompasses variants of SEQ ID NO: 1 that have the same function as the Clover-SAA1 protein. These variants include (but are not limited to): deletions, insertions, and / or substitutions of one or more amino acids (generally 1-50, preferably 1-30, more preferably 1-20, and most preferably 1-10), as well as the addition of one or more amino acids (generally within 20, preferably within 10, and more preferably within 5) to the C-terminus and / or N-terminus. For example, substitutions with amino acids having similar or similar properties generally do not alter protein function. For another example, the addition of one or more amino acids to the C-terminus and / or N-terminus generally does not alter protein function. The term also encompasses active fragments and derivatives of the Clover-SAA protein.
[0088] The present invention also provides other polypeptides, such as fusion proteins comprising the Clover-SAA1 protein or a fragment thereof (e.g., the fusion protein set forth in SEQ ID NO: 1). In addition to substantially full-length polypeptides, the present invention also encompasses soluble fragments of the Clover-SAA protein. Typically, such fragments comprise at least about 200 contiguous amino acids of the Clover-SAA protein sequence, typically at least about 250 contiguous amino acids, and preferably at least about 300 contiguous amino acids.
[0089] The invention also provides analogs of Clover-SAA1 protein or polypeptide. The differences between these analogs and natural SAA proteins can be differences in amino acid sequence, differences in modification forms that do not affect the sequence, or both. Induced variants can be obtained by various techniques, such as random mutagenesis by radiation or exposure to mutagens, site-directed mutagenesis or other known molecular biology techniques. Analogs also include analogs with residues different from natural L-amino acids (such as D-amino acids), as well as analogs with non-natural or synthetic amino acids (such as β, γ-amino acids). It should be understood that the polypeptides of the present invention are not limited to the representative polypeptides exemplified above.
[0090] Modifications (generally without altering the primary structure) include chemical derivatization of polypeptides in vivo or in vitro, such as acetylation or carboxylation. Modifications also include glycosylation, such as those resulting from polypeptide synthesis and processing or further processing steps. Such modifications can be accomplished by exposing the polypeptide to glycosylation enzymes (e.g., mammalian glycosylases or deglycosylases). Modifications also include sequences containing phosphorylated amino acid residues (e.g., phosphotyrosine, phosphoserine, and phosphothreonine). Also included are polypeptides modified to increase their resistance to proteolysis or optimize their solubility.
[0091] In the present invention, a "conservative variant polypeptide of the Clover-SAA protein" refers to a polypeptide having no more than 10, preferably no more than 8, more preferably no more than 5, and most preferably no more than 3 amino acids replaced with amino acids having similar or similar properties, compared to the amino acid sequence of SEQ ID NO: 1 or its core sequence (i.e., Z1-L1-Z2). These conservative variant polypeptides are preferably generated by amino acid substitutions according to Table 1.
[0092] Table 1
[0093] Initial residue Representative replacement Preferred substitutions Ala(A) Val; Leu; Ile Val Arg(R) Lys; Gln; Asn Lys Asn(N) Gln; His; Lys; Arg Gln Asp(D) Glu Glu Cys(C) Ser Ser Gln(Q) Asn Asn Glu(E) Asp Asp Gly(G) Pro; Ala Ala His(H) Asn; Gln; Lys; Arg Arg Ile(I) Leu; Val; Met; Ala; Phe Leu Leu(L) Ile; Val; Met; Ala; Phe Ile Lys(K) Arg; Gln; Asn Arg Met(M) Leu; Phe; Ile Leu Phe(F) Leu; Val; Ile; Ala; Tyr Leu Pro(P) Ala Ala Ser(S) Thr Thr Thr(T) Ser Ser Trp(W) Tyr; Phe Tyr Tyr(Y) Trp; Phe; Thr; Ser Phe Val(V) Ile;Leu;Met;Phe;Ala Leu
[0094] The polynucleotides of the present invention may be in the form of DNA or RNA. DNA forms include artificially synthesized DNA. DNA may be single-stranded or double-stranded. DNA may be a coding strand or a non-coding strand. The coding region sequence encoding the mature polypeptide may be identical to the coding region sequence set forth in SEQ ID NO:6 or a degenerate variant. As used herein, "degenerate variant" in the present invention refers to, for example, a nucleic acid sequence that encodes a protein having SEQ ID NO:6 but differs from the coding region sequence set forth in SEQ ID NO:6.
[0095] The polynucleotide encoding the mature polypeptide includes: a coding sequence that encodes only the mature polypeptide (i.e., Z1-L1-Z2); a coding sequence for the mature polypeptide and various additional coding sequences; a coding sequence for the mature polypeptide (and optional additional coding sequences) and non-coding sequences.
[0096] The term "polynucleotide encoding a polypeptide" may include a polynucleotide encoding the polypeptide, or may also include additional coding and / or non-coding sequences.
[0097] The present invention also relates to variants of the aforementioned polynucleotides, which encode polypeptides having the same amino acid sequence as the polypeptides of the present invention, or fragments, analogs, and derivatives thereof. As is known in the art, an allelic variant is an alternative form of a polynucleotide, which may contain one or more nucleotide substitutions, deletions, or insertions that do not substantially alter the function of the encoded polypeptide.
[0098] The polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and more preferably purified to homogeneity.
[0099] The full-length Clover-SAA nucleotide sequence or fragments thereof of the present invention can generally be obtained by PCR amplification, recombinant methods, or synthetic methods. For PCR amplification, primers can be designed based on the nucleotide sequence disclosed herein, particularly the open reading frame sequence, and the relevant sequence can be amplified using methods known to those skilled in the art.
[0100] Once the relevant sequence is obtained, it can be obtained in large quantities by recombinant methods. This is usually done by cloning it into a vector, then transferring it into cells, and then isolating the relevant sequence from the propagated host cells by conventional methods.
[0101] In addition, the sequences can also be synthesized by artificial synthesis, especially when the fragment length is shorter. Usually, a long fragment can be obtained by synthesizing multiple small fragments and then connecting them.
[0102] Currently, DNA sequences encoding proteins of the present invention (or fragments thereof, or derivatives thereof) can be obtained entirely by chemical synthesis. This DNA sequence can then be introduced into various existing DNA molecules (or vectors) and cells known in the art. In addition, mutations can also be introduced into protein sequences of the present invention by chemical synthesis.
[0103] Methods using PCR technology to amplify DNA are preferably used to obtain the genes of the present invention. Primers used for PCR can be appropriately selected based on the sequence information of the present invention disclosed herein and can be synthesized using conventional methods. Amplified DNA / RNA fragments can be separated and purified using conventional methods, such as by gel electrophoresis.
[0104] The present invention also relates to a vector comprising the polynucleotide of the present invention, a host cell produced by genetic engineering using the vector of the present invention or the coding sequence of the Clover-SAA protein, and a method for producing the polypeptide of the present invention by recombinant technology.
[0105] The polynucleotide sequences of the present invention can be used to express or produce recombinant Clover-SAA protein using conventional recombinant DNA techniques. Generally, the following steps are involved:
[0106] (1) Transforming or transducing a suitable host cell with a polynucleotide encoding the Clover-SAA protein (or variant) of the present invention, or a recombinant expression vector containing the polynucleotide;
[0107] (2) Host cells cultured in a suitable culture medium;
[0108] (3) Isolate and purify proteins from culture medium or cells.
[0109] In the present invention, the polynucleotide sequence of the Clover-SAA protein can be inserted into a recombinant expression vector. The term "recombinant expression vector" refers to bacterial plasmids, bacteriophages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses, or other vectors well known in the art. Vectors suitable for use in the present invention include, but are not limited to: T7-based expression vectors for expression in bacteria (Rosenberg, et al. Gene, 1987, 56: 125); pMSXND expression vectors for expression in mammalian cells (Lee and Nathans, J Bio Chem. 263: 3521, 1988); and baculovirus-derived vectors for expression in insect cells. In short, any plasmid or vector can be used as long as it can replicate and be stable in the host. An important feature of an expression vector is that it usually contains an origin of replication, a promoter, a marker gene, and translation control elements.
[0110] Methods well known to those skilled in the art can be used to construct expression vectors containing the DNA sequence encoding the Clover-SAA protein and appropriate transcriptional / translational control signals. These methods include in vitro recombinant DNA techniques, DNA synthesis techniques, in vivo recombination techniques, and the like (Sambroook et al. Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1989). The DNA sequence can be operably linked to an appropriate promoter in the expression vector to direct mRNA synthesis. Representative examples of these promoters include the lac or trp promoters of Escherichia coli; the lambda phage PL promoter; eukaryotic promoters including the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoter, retroviral LTRs, and other known promoters that control gene expression in prokaryotic or eukaryotic cells or their viruses. The expression vector also includes a ribosome binding site for translation initiation and a transcription terminator.
[0111] In addition, the expression vector preferably contains one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells, such as dihydrofolate reductase, neomycin resistance, and green fluorescent protein (GFP) for eukaryotic cell culture, or tetracycline or ampicillin resistance for Escherichia coli.
[0112] A vector containing the above-mentioned appropriate DNA sequence and an appropriate promoter or control sequence can be used to transform an appropriate host cell to enable it to express the protein.
[0113] Host cells can be prokaryotic cells, such as bacterial cells; lower eukaryotic cells, such as yeast cells; or higher eukaryotic cells, such as mammalian cells. Representative examples include Escherichia coli, Streptomyces; bacterial cells of Salmonella typhimurium; fungal cells, such as yeast; plant cells; insect cells such as Drosophila S2 or Sf9; and animal cells such as CHO, COS, 293 cells, or Bowes melanoma cells.
[0114] When the polynucleotides of the present invention are expressed in higher eukaryotic cells, transcription will be enhanced if an enhancer sequence is inserted into the vector. Enhancers are cis-acting DNA factors, typically about 10 to 300 base pairs in length, that act on promoters to increase gene transcription. Examples include the SV40 enhancer (100 to 270 base pairs on the late replication origin side), the polyoma enhancer on the late replication origin side, and adenovirus enhancers.
[0115] Those skilled in the art will appreciate how to select appropriate vectors, promoters, enhancers and host cells.
[0116] Transformation of host cells with recombinant DNA can be performed using conventional techniques well known to those skilled in the art. When the host is a prokaryotic organism such as Escherichia coli, competent cells capable of absorbing DNA can be harvested after the exponential growth phase and treated with CaCl2, using procedures well known in the art. Another method is to use MgCl2. If desired, transformation can also be performed using electroporation. When the host is a eukaryotic organism, the following DNA transfection methods can be used: calcium phosphate coprecipitation, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.
[0117] The obtained transformants can be cultured using conventional methods to express the polypeptide encoded by the gene of the present invention. Depending on the host cell used, the culture medium used can be selected from various conventional culture media. Culture is carried out under conditions suitable for the growth of the host cells. After the host cells grow to an appropriate cell density, the selected promoter is induced using a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
[0118] The recombinant polypeptide in the above method can be expressed intracellularly, on the cell membrane, or secreted extracellularly. If necessary, the recombinant protein can be isolated and purified by various separation methods utilizing its physical, chemical, and other properties. These methods are well known to those skilled in the art. Examples of these methods include, but are not limited to, conventional renaturation treatment, treatment with a protein precipitant (salting out method), centrifugation, osmotic sterilization, ultrafiltration, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC), and various other liquid chromatography techniques and combinations of these methods.
[0119] Application of the fusion protein of the present invention
[0120] The fusion protein of the present invention has good stability and can be visualized, and can be used for biological research, development of treatment strategies, drug screening, etc.
[0121] (1) Biological research: Those skilled in the art can use the fusion protein of the present invention to track the distribution and dynamics of SAA in cells, as well as its interactions with other proteins, in real time according to common technical means.
[0122] (2) Development of therapeutic strategies: The SAA fragments prepared by the present invention can better study the effects of SAA inhibitors or regulators, which is helpful for the development of new drugs for inflammatory-related diseases.
[0123] (3) Drug screening: Fluorescently labeled SAA fragments can be used to screen potential drug candidates during the drug discovery process and accelerate the development of new treatments.
[0124] The main advantages of the present invention include:
[0125] (1) The Clover-SAA1 protein of the present invention has good stability and can be visualized.
[0126] (2) The method of the present invention can express Clover-SAA1 protein at a high level, and the optimized purification steps can obtain high-purity Clover-SAA1 protein.
[0127] (3) The method of the present invention has no risks of cross infection, gene mutation, etc.
[0128] (4) The method of the present invention has simple operation steps and high efficiency.
[0129] (5) The Clover-SAA1 protein of the present invention has good safety and can be widely used in research fields such as disease diagnosis, drug screening, and biomarkers.
[0130] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.
[0131] Example
[0132] Preparation of fluorescent protein-labeled human serum amyloid protein
[0133] In this example, human serum amyloid protein was expressed and purified using a mammalian cell protein expression system (Expi293f cells).
[0134] Using the human SAA1.5 cDNA sequence as a template, the SAA1.5 sequence fragment (SAA11-58) corresponding to the human SAA secretion signal peptide, fusion protein tags (His tag, SUMO tag), and the fluorescent protein Clover sequence were cloned into the PMlink plasmid vector. Recombinant plasmids were constructed through restriction enzyme digestion, ligation, transformation, plasmid extraction, and sequencing. After sequencing, the recombinant plasmid was extracted using an Endo-free plasmid extraction kit for transfection.
[0135] Nucleotide sequence encoding SAA11-58:
[0136] TTTGATGGTGCTAGAGATATGTGGAGAGCTTATTCTGATATGAGAGAAGCTA
[0137] ATTATATTGGTTCTGATAAATATTTTCATGCTAGAGGTAATTATGATGCTGCT AAAAGAGGTCCAGGTGGTGCTTGGGCTGCTGAAGTTATT (SEQ ID NO: 4) encodes the nucleotide sequence of the fluorescent protein Clover:
[0138] GTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAG
[0139] CTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTCCGCGGCGAGGGCGAG
[0140] GGCGATGCCACCAACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGC
[0141] AAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCTTCGGCTACGGCGTGG
[0142] CCTGCTTCAGCCGCTACCCGACCACATGAAGCAGCACGACTTCTTCAAGTC
[0143] CGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTCTTTCAAGGACGA
[0144] CGGTACCTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGT
[0145] GAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCT
[0146] GGGGCACAAGCTGGAGTACAACTTCAACAGCCACAACGTCTATATCACGGC
[0147] CGACAAGCAGAAGAACGGCATCAAGGCTAACTTCAAGATCCGCCACAACGT
[0148] TGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCAT
[0149] CGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCCATCAGTCC
[0150] GCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATTACACATGGCATGGACGAGCTGTACAAG(SEQ ID NO:5)
[0151] Nucleotide sequence encoding the fusion protein of the present invention:
[0152] CATCATCATCATCATCATCATCATTCTGATTCTGAAGTTAATCAAGAAGCTA
[0153] AACCAGAAGTTAAACCAGAAGTTAAACCAGAAACTCATATTAATTTGAAAG
[0154] TTTCTGATGGTTCTTCTGAAATTTTTTTTAAAATTAAAAAAACTACTCCATTG
[0155] AGAAGATTGATGGAAGCTTTTGCTAAAAGACAAGGTAAAGAAATGGATTCT
[0156] TTGAGATTTTTGTATGATGGTATTAGAATACAAGCTGATCAAACTCCAGAAG
[0157] ATTTGGATATGGAAGATAATGATATTATTGAAGCTCATAGAGAACAAATTG
[0158] GTGGTGAAAATTTATATTTTCAGTCGGTGAGCAAGGGCGAGGAGCTGTTCAC
[0159] CGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAA
[0160] GTTCAGCGTCCGCGGCGAGGGCGAGGGCGATGCCACCAACGGCAAGCTGAC
[0161] CCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTC
[0162] GTGACCACCTTCGGCTACGGCGTGGCCTGCTTCAGCCGCTACCCCGACCACA
[0163] TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGG
[0164] AGCGCACCATCTCTTTCAAGGACGACGGTACCTACAAGACCCGCGCCGAGG
[0165] TGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCG
[0166] ACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTTCA
[0167] ACAGCCACAACGTCTATATCACGGCCGACAAGCAGAAGAACGGCATCAAGG
[0168] CTAACTTCAAGATCCGCCACAACGTTGAGGACGGCAGCGTGCAGCTCGCCG
[0169] ACCACTACCAGCAGAACACCCCATCGGCGACGGCCCCGTGCTGCTGCCCG
[0170] ACAACCACTACCTGAGCCATCAGTCCCGCCCTGAGCAAAGACCCCAACGAGA
[0171] AGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATTACAC
[0172] ATGGCATGGACGAGCTGTACAAGTTTGATGGTGCTAGAGATATGTGGAGAG
[0173] CTTATTCTGATATGAGAGAAGCTAATTATATTGGTTCTGATAAATATTTTCAT
[0174] GCTAGAGGTAATTATGATGCTGCTAAAAGAGGTCCAGGTGGTGCTTGGGCTGCTGAAGTTATT(SEQID NO:6)
[0175] In this example, three recombinant plasmids were designed, namely Plink-Kozak-signal peptide-His-UMOTEV-SAA1158, Plink-Kozak-signal peptide-His-SUMO-TEV-Clover-SAA1158 and PMlink-Kozak-signal peptide-His-SUMO-TEV-SAA1158-Clover ( Figure 1 、 2 and 3).
[0176] The recombinant plasmid was transfected into Expi293f mammalian cells using the chemical transfection reagent PEI 4000. The transfected cells were cultured at 37°C, 5% CO2 for 24 hours, and sodium butyrate solution was added to induce stimulation to increase protein expression yield.
[0177] 48 hours after transfection, the transfected cells were collected by centrifugation at 2500 × g for 10 minutes, the supernatant was discarded, and the collected cell pellet was resuspended in lysis buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl) containing protease inhibitors (2 μg / ml aprotinin, 2 μg / ml pepstatin, 2 μg / ml leupeptin, and 1 mM PMSF). All subsequent steps were performed at 4°C. The collected cell pellet suspension was disrupted using ultrasound or a high-pressure cell disruptor to release the cell contents. The supernatant was then centrifuged at 18,000 × g at 4°C for 45 minutes to separate the cell debris pellet from the cell lysis supernatant.
[0178] Subsequently, nickel column affinity chromatography was used to purify the recombinant protein from the supernatant after cell lysis. First, the supernatant after cell lysis was incubated with the nickel column at 4°C for 1 hour, and then the incubated nickel column was washed with wash buffer (20mM Tris-HCl pH 8.0, 150mM NaCl, 10mM imidazole) to remove impurities with weak affinity. Finally, the target protein bound to the nickel column was eluted with elution buffer (20mM Tris-HCl pH 8.0, 150mM NaCl, 250mM imidazole). The eluted protein was detected by SDS-PAGE gel electrophoresis and Coomassie Brilliant Blue staining. A short peptide of a specific segment of human serum amyloid A1 (SAA1) labeled with fluorescent protein was successfully purified.
[0179] Amino acid sequence of Clover-SAA1 protein:
[0180] HHHHHHHHSDSEVNQEAKPEVKPEVKPETHINLKVSDGSSEIFFKIKKTTPLRRL
[0181] MEAFAKRQGKEMDSLRFLYDGIRIQADQTPEDLDMEDNDIIEAHREQIGGENLY
[0182] FQSVSKGEELFTGVVPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTG
[0183] KLPVPWPPTLVTTFGYGVACFSRYPDHMKQHDFFKSAMPEGYVQERTISFKDDG
[0184] TYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYITADKQK
[0185] NGIKANFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSHQSALSKDPN
[0186] EKRDHMVLLEFVTAAGITHGMDELYKFDGARDMWRAYSDMREANYIGSDKYFHARGNYDAAKRGPGGAWAAEVI(SEQ ID NO:1)
[0187] Amino acid sequence of SAA11-58:
[0188] FDGARDMWRAYSDMREANYIGSDKYFHARGNYDAAKRGPGGAWAAEVI(SEQ ID NO:2)
[0189] Amino acid sequence of fluorescent protein Clover:
[0190] VSKGEELFTGVVPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTGKLP
[0191] VPWPPTLVTTFGYGVACFSRYPDHMKQHDFFKSAMPEGYVQERTISFKDDGTYK
[0192] TRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYITADKQKNGI
[0193] KANFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSHQSALSKDPNEKRDHMVLLEFVTAAGITHGMDELYK(SEQ ID NO:3)
[0194] result
[0195] SDS-PAGE gel electrophoresis images ( Figure 4 、 Figure 5 and Figure 6 ), the stability of the fusion protein was significantly improved compared with that without Clover fluorescent protein tag and Cover fluorescent protein tag placed at the C-terminus of the recombinant SAA protein fragment.
[0196] Figure 5 and 6The band marked by a red arrow in the figure shows the expected size of the target protein. Compared with the fusion protein without Clover fluorescent protein tag and the N-terminal tag, the C-terminally tagged fusion protein showed a diffuse protein product (approximately 40-55 kDa) on the gel, indicating that the fluorescent protein Clover at the C-terminus can effectively reduce the degradation of SAA protein fragments.
[0197] like Figure 5 As shown, when the recombinant SAA protein fragment was tagged with a fluorescent protein at the N-terminus, a diffuse protein product was formed, indicating an unstable protein structure. In contrast, the SAA protein tagged with a fluorescent protein at the C-terminus was structurally stable. These results suggest that the specific ligation method can affect the purification results of the fusion protein, such as its stability.
[0198] discuss
[0199] Clover fluorescent protein, a stable protein marker, significantly increased the stability of the SAA protein fragment in this example. This may be due to Clover providing additional structural support in the fusion protein construct or altering the surface properties of the protein, thereby reducing protease access and degradation.
[0200] Furthermore, the addition of Clover may affect the spatial structure of the protein, thereby affecting its degradation dynamics. This discovery has important implications for improving the stability of protein drugs and research tools, and may provide new strategies for the expression and purification of similar proteins.
[0201] The preparation method of the present invention provides new perspectives and tools for biological research, disease diagnosis and development of treatment strategies.
[0202] (1) Biological research: In the field of basic science, researchers can use the recombinant protein of the present invention to gain a deeper understanding of its biological functions and its role in inflammatory responses. Through fluorescent labeling, researchers can track the distribution and dynamics of SAA in cells in real time, as well as how it interacts with other proteins. For example, SAA protein can bind to LPS and form a complex and promote the clearance of LPS, but the specific mechanism is still unclear. The specific mechanism by which SAA promotes LPS clearance can be explored by co-incubating fluorescently labeled SAA-LPS complexes with cells. At the same time, it can also be applied to mouse disease models, and fluorescently labeled SAA protein can be added to allow SAA protein to bind to LPS, thereby promoting the clearance of LPS and alleviating LPS-induced inflammation. That is, the immune cells involved in the reaction and the signaling pathways that may be involved can be intuitively tracked by fluorescent labeling. In addition, high-purity SAA fragments enable more accurate structure-function relationship studies, which is crucial for decoding how SAA participates in pathological processes.
[0203] (2) Development of therapeutic strategies: Regulation of SAA plays an important role in the treatment of diseases, particularly those associated with chronic inflammation, such as cardiovascular disease, rheumatoid arthritis, and inflammatory bowel disease. The SAA fragments prepared by this invention can better investigate the effects of SAA inhibitors or modulators, facilitating the development of new drugs for inflammatory diseases.
[0204] (3) Drug screening: In addition, fluorescently labeled SAA fragments can be used to screen potential drug candidates during the drug discovery process, accelerating the development of new treatments. (SAA interacts with a variety of lipid molecules and can be used to screen potential drug candidates)
[0205] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.
Claims
1. A fusion protein, characterized in that The fusion protein has the structure shown in Formula I: Z0-Z1-L1-Z2(I) Where, Z0 is a tag sequence used for purification and separation purposes; Z1 is a fragment of human serum amyloid A protein; L1 is none or connector; Z2 is a fluorescent protein.
2. The fusion protein according to claim 1, wherein The human serum amyloid A protein fragment has an amino acid sequence at positions 11 to 58 of the wild-type human serum amyloid A1 amino acid sequence.
3. The fusion protein according to claim 1, wherein The fusion protein has the amino acid sequence shown in SEQ ID NO:
1.
4. The fusion protein according to claim 1, wherein The fluorescent protein has an amino acid sequence as shown in SEQ ID NO:
3.
5. The fusion protein according to claim 1, wherein The fluorescent protein is CLOVER protein.
6. A polynucleotide, characterized in that The polynucleotide encodes the fusion protein according to claims 1 to 5.
7. A carrier, characterized in that The vector contains the polynucleotide according to claim 6.
8. A host cell, characterized in that The host cell contains the vector according to claim 7 or the polynucleotide according to claim 6 is integrated into its genome.
9. Use of the fusion protein according to claims 1 to 5, characterized in that: The fusion protein is used for preparing a preparation for diagnosing human serum amyloid protein-related diseases.
10. A method for preparing the fusion protein according to claims 1 to 5, characterized in that: The method comprises the following steps: Under conditions suitable for expression, the host cell according to claim 8 is cultured, expression is induced, and purification is performed to obtain the fusion protein.
Citation Information
Patent Citations
Human serum amyloid A1 functional short peptide as well as preparation method and application thereof
CN108727484A
Human serum amyloid a fusion gene and human serum amyloid a fusion protein
JP2016002053A
